Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 6/20 | 0.56 |
| ▸ | MMP2 | P08253 | 4/20 | 0.56 |
| ▸ | MMP14 | P50281 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4271585 | 0.85 | HRH4 (0.57) | HRH4HRH3ALOX15HTTRIPK1 | |
| SCHEMBL31088687 | 0.85 | HRH4 (0.57) | HRH4HRH3ALOX15HTTRIPK1 | |
| Hydrochloric Acid SCHEMBL1879831 | 0.84 | HRH4 (0.56) | HRH4HRH3ALOX15HTTRIPK1 | |
| SCHEMBL30853474 | 0.82 | RAB9A (0.54) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL253780 | 0.82 | ALDH1A1 (0.54) | KDM4EALDH1A1NPC1LMNAGAA | |
| SCHEMBL16505827 | 0.82 | RAB9A (0.54) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL7684022 | 0.82 | EGLN1 (0.52) | RAB9ALMNAMAPTKMT2AMMP2 | |
| SCHEMBL12647218 | 0.81 | HRH4 (0.56) | HRH4HRH3RIPK1CNR2DAO | |
| SCHEMBL30436104 | 0.79 | ALOX15 (0.56) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL14208295 | 0.79 | ALOX15 (0.56) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312938-A1 | Pyrrolopyridine Carboxylic Acid Derivatives | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | claimed |
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | Jubilant Epipad LLC | 2025-10-02 | — | — | US | disclosed |
| US-12357639-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2025-07-15 | — | — | US | disclosed |
| EP-3885342-B1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| US-12076411-B2 | Anti-HER2 antibody-maytansine conjugates and methods of use thereof | REDWOOD BIOSCIENCE, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-115703792-B | Tricycle derivative and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | VINCERE BIOSCIENCES, INC. | 2024-08-08 | — | — | US | disclosed |
| US-20240156831-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC | 2024-05-16 | — | — | US | disclosed |
| EP-3684767-B1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-3684767-B1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2005000849-A1 | 5HT2C RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| EP-1472255-A1 | AZA-ARYLPIPERAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| US-6800627-B1 | CENTRAL NERVOUS SYSTEM, CARDIOVASCULAR AND GASTROINTESTINAL DISORDERS, DIABETES INSPIDUS, SLEEP APNEA | VERNALIS RESEARCH LIMITED (GB) | 2004-10-05 | — | — | US | disclosed |
| US-20040092525-A1 | Pirazino(aza)indole derivatives | VERNALIS RESEARCH LIMITED | 2004-05-13 | — | — | US | disclosed |
| US-20040039200-A1 | Pirazino(AZA)indole derivatives | VERNALIS RESEARCH LIMITED | 2004-02-26 | — | — | US | disclosed |
| US-20030207888-A1 | Piperazine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-11-06 | — | — | US | disclosed |
| WO-2003064423-A1 | AZA-ARYLPIPERAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-07 | — | — | WO | disclosed |
| EP-1147110-B1 | PYRAZINO(AZA)INDOLE DERIVATIVES | VERNALIS RES LTD (GB) | 2003-05-07 | — | — | EP | disclosed |
| EP-1147110-A1 | PYRAZINO(AZA)INDOLE DERIVATIVES | VERNALIS RESEARCH LIMITED (GB) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044753-A1 | PIRAZINO(AZA)INDOLE DERIVATIVES | VERNALIS RESEARCH LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | NES, VHL, ETV6 | KDM4E 2928/4885ALDH1A1 2833/4885HPGD 1666/4885 |
| US-20240156831-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | PADI4, PADI2, PADI1 | KDM4E 341/4885ALDH1A1 86/4885HPGD 582/4885 |
| US-20040092525-A1 | Pirazino(aza)indole derivatives | PIR, GPR119, INMT | KDM4E 1333/4885ALDH1A1 452/4885HPGD 764/4885 |
| US-20030207888-A1 | Piperazine derivatives | GPR119, CPT1B, CYP2E1 | KDM4E 2114/4885ALDH1A1 36/4885HPGD 1063/4885 |
| US-12076411-B2 | Anti-HER2 antibody-maytansine conjugates and methods of use thereof | ERBB2, EGFR, ERBB3 | KDM4E 2372/4885ALDH1A1 1950/4885HPGD 1512/4885 |
| US-12357639-B2 | Heterocyclic compounds as pad inhibitors | PADI4, PADI2, PADI1 | KDM4E 341/4885ALDH1A1 86/4885HPGD 582/4885 |
| US-20040039200-A1 | Pirazino(AZA)indole derivatives | PIR, GPR119, INMT | KDM4E 1333/4885ALDH1A1 452/4885HPGD 764/4885 |
| US-20240262792-A1 | USP30 INHIBITORS AND USES THEREOF | USP30, USP28, USP1 | KDM4E 732/4885ALDH1A1 2021/4885HPGD 3509/4885 |
| US-20110312938-A1 | Pyrrolopyridine Carboxylic Acid Derivatives | SDHA, ALDH5A1, SDHB | KDM4E 3282/4885ALDH1A1 50/4885HPGD 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.